Microbix mobilizes SWATT team to help companies worldwide expand flu vaccine production
The SWATT team will be sent to facilities adopting the Microbix proprietary virus yield enhancement technology - VIRUSMAX(TM). The team is expected to be operational this Fall. It will spend several weeks in each location helping customers implement the technology and training local personnel.
At present, only about 350 million doses of flu vaccine are produced annually in the world. There are only three countries that produce enough vaccine domestically to immunize their populations - Canada, France, and Australia. Every other country lacks the manufacturing capacity to meet its own needs. The largest domestic deficits are the U.S., China and India.
According to the company, Microbix' technology has been proven to double vaccine production output. It was also announced that Australia has indicated that it will issue a patent on this technology to Microbix. Similar patent protection has already been allowed in the U.S., Canada and India, and a number of other applications in major markets are currently pending.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.